Transdermal Drug Delivery System of Antidiabetic Drugs: A Review

Diabetes is chronic metabolic disorder, resulting from insulin deficiency, characterized by hyperglycaemia, altered metabolism of carbohydrate, protein and lipids and an increased risk of vascular complication. The disadvantage of antidiabetic drugs such as more frequent of administration, extensive first passes metabolism and variable bioavailability, makes it is an ideal candidate for transdermal drug delivery systems. This article is dedicated to the review of antihypertensive transdermal patches in the perspective of enhancing the bioavailability as well as in improving the patient compliance. The various antidiabetic drugs sulfonylurea's (SU), biguanides, meglitinide, thiazolidinediones (TZDs) Currently a number of antidiabetic transdermal patches are introduced in to the pharmaceutical market. Most of the reported methods in the literature employed solvent evaporation method or solvent casting method for the preparation of transdermal patches. Depending on the release required over a period of time, the concentrations of polymer, plasticizer and penetrant were varied.